CAR-T cell therapy - overview & toxicity
CAR-T · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chimeric antigen receptor T-cell therapy uses genetically engineered autologous T cells to target tumour antigens (e.g. CD19, BCMA) in refractory lymphoma, leukaemia and myeloma. Its hallmark toxicities are cytokine release syndrome and neurotoxicity, needing specialist recognition.
Red flags
- High fever with hypotension/hypoxia (severe CRS)
- Falling consciousness, seizures, dysphasia (severe ICANS)
- Features of HLH/macrophage activation (very high ferritin, cytopenias)
- Tumour lysis syndrome
- Neutropenic sepsis
Assessment
Differential diagnosis
- Cytokine release syndrome vs sepsis
- ICANS vs CNS infection / metabolic encephalopathy
- Tumour lysis syndrome
- Macrophage activation / HLH
- Infusion reaction
Investigations
- Baseline and serial FBC, CRP, ferritin, fibrinogen (CRS/HLH markers)
- Renal, liver function and tumour lysis labs
- Neurological assessment with ICE score for ICANS
- Blood cultures/septic screen (overlap with CRS)
- Coagulation screen
- Imaging/EEG/CSF for severe neurotoxicity
Management
- Select eligible patients (refractory/relapsed CD19+ B-cell malignancies, BCMA+ myeloma) at an accredited centre
- Harvest T cells by apheresis, manufacture the product, and bridge disease as needed
- Give lymphodepleting chemotherapy before infusion
- Admit for infusion with intensive monitoring for CRS and neurotoxicity
- Grade and treat cytokine release syndrome: supportive care, tocilizumab for significant CRS, add corticosteroids if severe/refractory
- Grade and treat ICANS primarily with corticosteroids (tocilizumab is less effective for neurotoxicity)
- Give tumour lysis prophylaxis and manage cytopenias and hypogammaglobulinaemia
- Provide antimicrobial prophylaxis and treat infections promptly (overlap with CRS)
- Monitor for prolonged cytopenias, B-cell aplasia and rare delayed neurotoxicity
- Arrange long-term follow-up for relapse and late effects
Drugs & doses
Tocilizumab 8 mg/kg IV (max 800 mg) for significant cytokine release syndrome, repeatable
Dexamethasone 10 mg IV (escalating) or methylprednisolone for severe CRS/ICANS
Lymphodepletion: fludarabine 30 mg/m2 + cyclophosphamide 300-500 mg/m2 IV for 3 days
Levetiracetam for seizure prophylaxis/treatment in ICANS; IVIg for hypogammaglobulinaemia
Disposition
Accredited CAR-T centre with inpatient monitoring; critical care for severe CRS/ICANS; structured long-term follow-up.
Complications & pitfalls
- Cytokine release syndrome
- Immune effector cell-associated neurotoxicity (ICANS)
- Prolonged cytopenias
- Hypogammaglobulinaemia and infections
- B-cell aplasia
- Relapse / antigen escape
Exam pearls
- CRS is managed with tocilizumab and steroids; ICANS responds better to steroids than tocilizumab
- CRS and sepsis look alike - treat for both until cultures clarify
- The ICE score standardises neurotoxicity grading
- Very high ferritin suggests overlapping HLH/macrophage activation
- Only accredited centres with trained teams should deliver CAR-T
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.